Advanced Medical Isotope Corporation (OTCMKTS:RDGL) Short Interest Update

Advanced Medical Isotope Corporation (OTCMKTS:RDGL) was the recipient of a large decline in short interest in August. As of August 31st, there was short interest totaling 10,391 shares, a decline of 87.4% from the August 15th total of 82,653 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average trading volume of 1,483,590 shares, the short-interest ratio is presently 0.0 days.

Advanced Medical Isotope Stock Performance

Shares of RDGL stock remained flat at $0.05 during trading on Friday. 950,695 shares of the stock were exchanged, compared to its average volume of 752,546. Advanced Medical Isotope has a twelve month low of $0.04 and a twelve month high of $0.12. The firm’s 50 day moving average is $0.06 and its two-hundred day moving average is $0.07. The stock has a market capitalization of $24.50 million, a P/E ratio of -4.96 and a beta of -0.72.

Advanced Medical Isotope Company Profile

Vivos Inc, a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc in December 2017. Vivos Inc was incorporated in 1994 and is headquartered in Richland, Washington.